

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Etilefrine hydrochloride (injection)

July 17, 2019

Therapeutic category

Cardiotonics

Non-proprietary name

Etilefrine hydrochloride

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
<p>Contraindications (N/A)</p>	<p>Contraindications <u>Patients with a history of hypersensitivity to any of the ingredients contained in this product</u></p>
<p>Relative Contraindications <u>Patients with a history of hypersensitivity to any of the ingredients contained in this product</u></p>	<p>Relative Contraindications (deleted)</p>

N/A: Not Applicable, because the section is not included in the current package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp